A new self-collecting device obtains approval from the FDA

Many women repel the cervical cancer screening because the process is often uncomfortable, clumsy or annoying. Finding time, missing work and fear of an invasive examination can be enough to repel it. But as cervical cancer is highly avoidable and treatable when taken early, regular screening remains essential to protect long -term health.

In a revolutionary change, the Sarcelle wand, the first auto-collect device approved by the FDA, allows women to collect their cervical sample in the intimacy of their house. This new alternative could simplify the screening process, allowing more women to take care of their health according to their own conditions, according to Teal Health, the company behind the device.

“Women can now perceive their own sample in the private life of the house, no speculum required, and post it to a laboratory certified to be tested on the same test as the doctor’s office, with the same precision,” Teal Health said in a press release.

The new device is supported by a large-scale study confirming that self-collected samples using the Sarcelle wand are just as effective as those collected by clinicians, detecting the 96% of the time. In particular, 94% of participants preferred the home method and 86% said that this would help them remain more consistent with screening.

According to Kara Egan, CEO and co-founder of Teal Health, FDA approval is significant not only because it presents an innovative product, but because it brings hope to women who often put their health last.

“It is not only a new innovative product, it is a question of finally giving women an option that makes sense for their life – something that can be done quickly and comfortably at home. Because when we make care that is easier to obtain, we help women stay healthy, for themselves and for people who count every day,” said Egan in a press release.

After receiving FDA approval, Teal Health works quickly to make the aircraft available to women across the country. They associate with the main insurers and offer flexible payment options. From June, prescription kits will be available in California, with plans to develop nationally shortly after for people aged 25 to 65 who are at an average risk of cervical cancer.